Key Insights• The South Korea biosurgery market represents one of the most dynamic and technologically advanced national markets for surgical biomaterials in Asia-Pacific. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.• The South Korea biosurgery market is distinguished by its universal healthcare system, world-class clinical infrastructure, and significant surgical volumes. According to the National Health Insurance Service's "2024 Major Surgery Statistics Yearbook," the total number of 35 major surgeries performed in South Korea reached 2,054,344 cases in 2024, representing a 0.4% increase from the previous year. Cataract surgery was the most common procedure, with 664,306 cases, followed by general spinal surgery with 202,099 cases and cesarean section with 160,804 cases. Healthcare expenditure in South Korea reached approximately 8.95% of GDP in 2025, having risen from 3.72% in 2000. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models.• Bone-Graft Substitutes represent the largest product category within the South Korean biosurgery market, driven by the high volume of orthopedic and spinal procedures.

General spinal surgery ranked as the second most common surgery with 202,099 cases. Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive surgical techniques. The minimally invasive surgery market in South Korea is expected to grow at a CAGR of 7.9% from 2025 to 2033.• South Korea's aging population represents the most significant long-term demand driver. As of 2025, 10.723 million people (20.7% of the population) were aged 65 years or older, marking the first time the elderly population has exceeded 20%. The country is now officially classified as a "super-aged society".The regulatory environment, centered on the Ministry of Food and Drug Safety (MFDS), is undergoing significant modernization. In 2025, the MFDS published the world's first Guidance on the Approval and Review of Generative AI Medical Devices.Market Outlook• According to the research report, "South Korea Biosurgery Market Overview, 2031 Overview, 2031," published by Actual Market Research, the South Korea Biosurgery market is expected to reach a market size of more than USD 331 Million by 2031.• South Korea's healthcare expenditure continues to rise, reaching approximately 8.95% of GDP in 2025, up from 3.72% in 2000.

Health insurance medical expenses rose 4.9% year-on-year to 116.23 trillion won ($79.29 billion) in 2024, with older adults accounting for 44.9% of all spending. Medical expenses for seniors aged 65 and above climbed to 52.19 trillion won, a 6.7% increase. The aging South Korean population represents the most significant long-term demand driver. As of 2025, 10.723 million people (20.7% of the population) were aged 65 years or older. The number of elderly increased by 601,000 (5.9%) in 2025. The working-age population (ages 15-64) fell below 70% for the first time to 69.2%, increasing pressure on healthcare services.• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market.

The South Korean government is actively promoting research and development in the healthcare sector. Regulatory frameworks are evolving to facilitate faster approvals for innovative therapies. The MFDS published the world's first Guidance on the Approval and Review of Generative AI Medical Devices in 2025. Rising surgical procedures and growing awareness of minimally invasive techniques are key drivers propelling market expansion. The minimally invasive surgery market in South Korea is expected to grow at a CAGR of 7.9% from 2025 to 2033, creating sustained demand for biosurgical products designed for minimally invasive applications.Market DynamicsDriver: High and Growing Surgical Volumes and Aging PopulationSouth Korea performs millions of surgical procedures annually across its extensive network of hospitals and healthcare facilities. According to the National Health Insurance Service, 2,054,344 major surgeries were performed in 2024, up 0.4% from the previous year.

Cataract surgery was the most common procedure with 664,306 cases, followed by general spinal surgery with 202,099 cases. The number of surgical patients was highest in their 60s with 399,038, followed by those in their 70s with 377,121. With 10.723 million people (20.7% of the population) aged 65 years or older and the country now classified as a "super-aged society," the demand for surgical interventions will continue to rise. Health insurance medical expenses reached 116.23 trillion won ($79.29 billion) in 2024, with older adults accounting for 44.9% of all spending. Medical expenses for seniors aged 65 and above climbed to 52.19 trillion won, a 6.7% increase.Challenge: Surgical Workforce Constraints and Healthcare Spending PressuresDespite the market's size and sophistication, South Korea faces significant workforce challenges that could impact surgical capacity. As of December 2024, the number of practicing physicians decreased by 4.7% year-on-year, making them the only category of healthcare personnel to record a decline.

This short-term workforce shrinkage coincided with mass trainee doctor resignations, exposing a widening gap between policy intentions and real-world outcomes. While the number of nurses increased by 4.9% and other healthcare personnel saw modest increases, the decline in practicing physicians could limit surgical volume growth and, consequently, biosurgical product demand. Additionally, the healthcare system faces pressures from a rapidly aging population, with the working-age population falling below 70% for the first time, potentially straining healthcare financing and service delivery.Trend: Accelerating Adoption of Minimally Invasive and Digital Health TechnologiesThe South Korean biosurgery market is experiencing a significant trend toward minimally invasive surgical techniques and digital health integration. The minimally invasive surgery market in South Korea is expected to grow at a CAGR of 7.9% from 2025 to 2033. South Korea is at the forefront of digital health innovation in medical devices. In 2025, the MFDS published the world's first Guidance on the Approval and Review of Generative AI Medical Devices.

This was followed by the issuance of guidelines on Labelling and Information Requirements for Digital Medical Devices and Classification and Risk Grading of Digital Medical Devices. The Digital Medical Products Act became effective in January 2025, providing a legal basis for digital medical products. This shift toward advanced surgical platforms and digital health creates new opportunities for biosurgical products specifically designed for minimally invasive applications and integrated with digital health solutions.Policies• The Ministry of Food and Drug Safety (MFDS) serves as the primary regulatory authority for medical devices in South Korea. In 2025, the MFDS published the "2025 Medical Device Approval Report" to introduce current trends of medical device approvals to overseas markets.• The Digital Medical Products Act became effective on January 31, 2025, providing a legal basis for digital medical products including AI-powered medical devices and software as a medical device.• The MFDS published the world's first Guidance on the Approval and Review of Generative AI Medical Devices in 2025, followed by guidelines on Labelling and Information Requirements for Digital Medical Devices and Classification and Risk Grading of Digital Medical Devices.• Amendments to the Enforcement Rules of the Medical Device Act were implemented between April and August 2025, including higher fees for innovative medical device reviews. Revised Medical Device Standards will take effect from July 4, 2026.• The National Health Insurance Service (NHIS) manages the national health insurance system covering 97.1% of the population. Health insurance medical expenses reached 116.23 trillion won ($79.29 billion) in 2024, a 4.9% increase.• Medical institutions in South Korea reached 103,308 in 2024, a 1.5% increase.

This includes 1,412 hospitals, 1,342 nursing hospitals, 331 general hospitals, and 47 tertiary general hospitals.Segment AnalysisSouth Korea Biosurgery Market By Product• Bone-Graft Substitutes represent the largest product category within the South Korean biosurgery market, driven by the high volume of orthopedic and spinal procedures. General spinal surgery ranked as the second most common surgery with 202,099 cases in 2024. Knee replacement surgery ranked among the highest in medical expenses at 847.3 billion won. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The aging South Korean population with 20.7% aged 65 and older continues to drive demand for musculoskeletal interventions requiring bone-graft substitutes.• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding.

With 2,054,344 major surgeries performed in 2024, demand for hemostatic products is substantial and growing.• Surgical Sealants and Adhesives represent the fastest-growing product category in the South Korean biosurgery market, driven by increasing adoption of minimally invasive surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The minimally invasive surgery market in South Korea is expected to grow at a CAGR of 7.9% from 2025 to 2033, supporting the expansion of this segment.• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. With cesarean section accounting for 160,804 cases in 2024, the category continues to benefit from the high volume of gynecological and abdominal procedures.• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in South Korean hospitals.• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage. The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.South Korea Biosurgery Market By Application• Orthopedic Surgery is the largest application area for biosurgical products in South Korea, driven by the high volume of spinal surgeries, joint replacements, and trauma procedures.

General spinal surgery ranked as the second most common surgery with 202,099 cases. Knee replacement surgery medical expenses reached 847.3 billion won. The aging population with 10.723 million aged 65 and older continues to drive demand for musculoskeletal interventions.• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair. Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers. Total major surgeries reached 2,054,344 cases in 2024.• Cardiovascular Surgery represents the fastest-growing application area in the South Korean biosurgery market, driven by the high prevalence of cardiovascular disease and the aging population. Heart surgery ranked among the highest in per-case expenses at 41.37 million won, while coronary artery bypass surgery was 37.01 million won.

The aging population continues to drive demand for cardiovascular interventions.• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. The aging population and increasing incidence of neurological conditions drive demand in this specialty.• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery.• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement. Cesarean section accounted for 160,804 cases in 2024, ranking as the third most common surgery.• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions.South Korea Biosurgery Market By Source/Origin• Biologic products represent the largest source category in the South Korean biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. The MFDS's rigorous requirements for biological materials ensure high safety standards and support market confidence.• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the South Korean market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats.

The South Korean healthcare system's emphasis on cost-effectiveness favors synthetic alternatives for certain applications.South Korea Biosurgery Market By End-User• Hospitals remain the largest end-user segment for biosurgical products in South Korea, accounting for the majority of revenue. Medical institutions reached 103,308 in 2024, including 1,412 hospitals, 1,342 nursing hospitals, 331 general hospitals, and 47 tertiary general hospitals. With 2,054,344 major surgeries performed in 2024, hospitals are the primary setting for biosurgical product utilization. Procedure and surgery accounted for 19.4% of medical and health center expenses, reflecting the central role of surgical care.• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the South Korean biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The average hospital stay per major surgery was 5.7 days, a decrease of 1.7% from the previous year, reflecting the trend toward shorter stays and increased outpatient procedures. Cataract surgery, the most common procedure with 664,306 cases, had the shortest hospital stay at 1.1 days.• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.

Clinics comprised the largest share of medical institutions at 36,685 facilities (46.9%).South Korea Biosurgery Market Economics• The South Korean biosurgery market operates within a universal healthcare system supported by national health insurance, centralized reimbursement, and strong cost-containment measures. National health insurance covers 97.1% of the population, while health insurance medical expenses reached 116.23 trillion won in 2024, increasing 4.9% year-on-year. Medical expenses for people aged 65 and above reached 52.19 trillion won, up 6.7%, while expenditure on 35 major surgeries reached 9.3075 trillion won. Manufacturers must demonstrate clinical efficacy, safety, and cost-effectiveness to secure favorable reimbursement and adoption in this competitive market.• Biosurgical products are procured through hospital agreements, group purchasing organizations, and surgeon preferences, with procurement consolidation increasing pricing competition. South Korea had 103,308 medical institutions in 2024, including 1,412 hospitals, 331 general hospitals, and 47 tertiary general hospitals, while clinics accounted for the largest facility category. Surgery represented 19.4% of medical and health-center expenditure, demonstrating substantial underlying demand.

The country also provides a sophisticated supply chain and advanced manufacturing environment, making it an attractive commercial and production hub for biosurgery companies seeking access to the broader Asia-Pacific market.• South Korea has a technologically advanced healthcare infrastructure and strong research ecosystem supporting biosurgical innovation. However, the practicing physician population declined 4.7% year-on-year in 2024, creating potential workforce constraints despite a 4.9% increase in nurses. Innovation is increasingly focused on digital health, AI-enabled medical devices, advanced biomaterials, and minimally invasive technologies. The Ministry of Food and Drug Safety (MFDS) introduced the Digital Medical Products Act in January 2025 and issued guidance for generative-AI medical devices. These developments strengthen the country’s position as an innovation-oriented medical technology market.• Technology adoption is accelerating across robotic-assisted surgery, minimally invasive procedures, advanced biomaterials, and digital medical technologies, with the South Korean minimally invasive surgery market projected to grow at a 7.9% CAGR from 2025 to 2033. Regulatory developments, including revised medical-device standards effective July 2026, are expected to further support innovation while maintaining safety requirements.

Long-term demand is strengthened by population aging, with 10.723 million people aged 65 and above, representing 20.7% of the population. The South Korea biosurgery market is expected to exceed USD 331 million by 2031, creating opportunities for manufacturers that successfully navigate reimbursement, procurement, and evolving digital-health regulations.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Biosurgery Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Bone-Graft Substitutes• Hemostatic Agents• Surgical Sealants & Adhesives• Adhesion Barriers• Soft-Tissue Attachments• Staple-Line ReinforcementBy Application:• Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more)By Source/Origin• Biologic• Synthetic / Semi-syntheticBy End-user:• Hospitals • Ambulatory Surgical Centers • Clinics • Others.